Productivity challenges are not new to the pharmaceutical industry. They have, however, been complicated by new pressures and industry-wide trends—from the staggering patent cliffs ahead and increased pressure from payers to the potential opportunities created by emerging global markets and health care consumerism. As a result, R&D organizations are looking at a challenging future. How can they survive in a do-better-with-less climate of reduced resources
and widespread cost cutting?
Now is the time for R&D organizations to rethink how they work—from changing operating models, to focusing on continuous improvement and reassessing funding and resource streams.